Abstract
Objective: This study assessed the impact of a fixed-dose combination 5α-reductase inhibitor (5-ARI) dutasteride 0.5 mg and the α-blocker (AB) tamsulosin 0.4 mg on erectile dysfunction (ED) using The International Index of Erectile Function-5 (IIEF-5) score and Erectile Hard Score (EHS) in patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Material & Methods: This was an analytical cross-sectional with consecutive sampling. We reviewed the medical records of the symptomatic BPH patients. Then we interviewed The International Prostate Symptom Score (IPSS), Quality of Life (QOL), IIEF-5, and EHS scores after administered combination therapy. The data were analyzed with SPSS IBM 21.0 using univariate and then bivariate analysis. Results: Forty (40) patients fulfilled inclusion criteria. The results showed that the frequency of patients at most in the age range of 50-59 years (40%), most of IPSS after therapy showed mild grade 45%, and moderate grade 55%. The QOL average score is 2.08, most of the patients felt pleased (35%). IIEF-5 average score after treatment is 11.6 (moderate ED) and the EHS is 2.48 (grade 2: tumescence with minimal rigidity). The Spearman test showed that there was no correlation between IPSS and IIEF-5, the score is -0.658. Then, the Spearman correlation score between BPH grade after combination treatment and ED grade is 0.739 and had a statistically significant 0.000 (p<0.001). Conclusion: This research shows that there is a correlation of the impact of tamsulosin/ dutasteride combination therapy on ED in BPH with secondary LUTS.
 Keywords: BPH, erectile dysfunction, tamsulosin/dutasteride combination.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
